



Disclaimer



This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company's future activities and performance. They include statements about future strategies and anticipated benefits of these strategies.

These statements are subject to risks and uncertainties. Actual results may differ substantially from those stated in any forward-looking statement. This is due to a number of factors, including the possibility that Orion may decide not to implement these strategies and the possibility that the anticipated benefits of implemented strategies are not achieved. Orion assumes no obligation to update or revise any information included in this presentation.

All the figures in this presentation have been rounded, which is why the total sums of individual figures may differ from the total sums shown.



Highlights in January-June 2020



Orion has fared well in exceptional circumstances

The COVID-19 pandemic increased demand for some products in March-April after which the demand has levelled off.

With the growth of net sales

also the operating profit increased. In addition,

milestones increased the

operating profit.



3

First commercial sales of Nubeqa® in Japan and the EU New data from ARAMIS study published at ASCO.

Vali dat

Validation of REFALS study data ongoing.

COVID-19 pandemic impacts on Orion

The most important thing is to take care of the health and safety of employees, the continuity of production and patient safety in ongoing clinical trials.



The March demand spike impact of Gx and OTC products is levelling off.



Disruptions in the global supply chains possible but the risk of impacts in 2020 lower.



Strong increase in demand in March-April after which demand returned to a more normal level.



Prioritisation in production managed with success. No bottlenecks currently.



The impact of March demand spike has levelled off.



Some delays in some R&D programs.





Net sales

572


MEUR (493) +16% Operating profit **181** MEUR (107) +69% Operating profit margin 32%


(22%)

Cash flow per share before financial items


> **0.90** EUR (0.57) +56%

Development of net sales and operating profit





* Product & service sales without sales margin and product mix change and exchange rate effect ** Product sales margin and product mix change but without exchange rate effect *** Exchange rate effect on gross margin



ORIO Proprietary and Specialty Products showed strong growth ■ 1-6/2020 ■ 1-6/2019 1-6/2020**MEUR** +9% +36% 7% 300 249 243 7% 230 250 200 178 42% 150 -7% +6% 100 44% 43 46 40 38 50 0 Proprietary Products Fermion and Specialty Proprietary Animal Specialty Products **Products Products** Health Contract Animal Health Manufacturing Fermion & CM


Best-selling pharmaceuticals 1-6/2020

		Indication	Net sales EUR million	Change vs. 1-6/2019
1.	EASYHALER	Asthma, COPD	61	+17%
2.	Stalevo Comtess COMTan	Parkinson's disease	53	+20%
3.	SIMDAX Tryosimendan	Acute heart failure	35	+0%
4.	dexdor	Intensive care sedative	34	+1%
5.		Animal sedatives	16	-26 %
6.	burana	Inflammatory pain	12	+1%
7.	Divina series Divina	Menopausal symptoms	10	+16%
8.	Trexan®	Rheumatoid arthritis, cancer	9	+83%
9.	Biosimilars (Remsima inflormability Ritering Ritering) Ritering	Rheumatoid arthritis, inflammatory bowel diseases, lymphoma	9	-53%
10.	Solomet®	Inflammation, pain	8	+33%

= Products of Proprietary Products unit









Proprietary Products




Dexdor® showed growth due to COVID-19



Proprietary Products sales split 1-6/2020



Easyhaler® sales +17%




■ Other ■ Budesonide-formoterol Easyhaler®

Parkinson's franchise sales +20%

1-6/2020 Own sales MEUR 24 (21) +18% 50 1-6/2020 Deliveries to partners MEUR 28 (23) +23% 45 40 **Sales, MEUR** 30 52 50 12 15 35 10 5 0 Q2 Q3 Q4 Q1 Q1 Q2 2015 2016 2017 2018 2019 2020 Orion own sales Deliveries to partners

Dexdor® and Simdax®




ORION



Specialty Products





In Finland, market for reference priced prescription drugs started to level off after demand spike in March

The market for reference priced prescription drugs in Finland (1-6/2020)

MEUR 219 (217)

Market development +1%




The sales of Orion's reference priced prescription drugs in Finland



Orion's development

Orion is strong in home market Finland

Human pharma market in Finland 1–6/2020 Medicinal and non-medicinal products in hospital and pharmacy channels: EUR 1,420 million



Reference priced prescription drugs Orion market share in pharmacy

25%

(25%)

Self-care products Orion market share in pharmacy



Human pharmaceuticals total Orion market share in hospital & pharmacy

(11%)



Research and development



Orion's key clinical drug development projects

Project	Indication		Phase		Registration
Easyhaler® tiotropium	COPD	Bioequivalence study			
Darolutamide ¹⁾	Prostate cancer (mHSPC)	1	II	Ш	
ODM-109 (oral levosimendan)	ALS	I.	II	Ш	
ODM-203 (targeted FGFR+VEGFR inhibitor) ²⁾	Solid tumours	I	П		
ODM-207 (BET protein inhibitor) ²⁾	Cancer	- I			
ODM-208 (CYP11A1 inhibitor)	Prostate cancer (CRPC)	1			
ODM-209 (CYP11A1 inhibitor)	Prostate cancer (CRPC), breast cancer	1			
¹⁾ In collaboration with Bayer		= (Completed		
²⁾ Search for partner ongoing for the next possible phase		= 0	Ongoing		= Status changed

More information on R&D projects: www.orion.fi/en/rd/orion-rd/pipeline/



ORION

Orion's key business targets in 2020

Commercialisation of darolutamide in Europe. ARASENS trial (metastatic prostate cancer) continues in order to expand the indication for the molecule.

- First commercial sales of darolutamide in Japan and the EU.
- Fully recruited ARASENS trial estimated to complete in 2021.

Development of orally administered levosimendan (ODM-109) for ALS in phase III clinical trial (REFALS) and preparation for its possible commercialisation. The potential of different R&D projects are reviewed with consideration of the total R&D portfolio.

2.

- Validation of the REFALS study data is ongoing.
- An assessment on the prospects of launching the product in the USA by Orion is ongoing.
- Searching for partners for development of ODM-203 and ODM-207.



Orion's key business targets in 2020

Strengthening Orion's position as the most significant provider of generic drugs in
Finland. Competitive product portfolio in Specialty Products and strengthening of product launches.

Accelerating the growth of the Easyhaler® product family and strengthening its market position. Salmeterol-fluticasone launch in Europe.

Evaluation of new in-licensingopportunities in Europe, particularly in the area of hospital care.

4.

- Orion is a clear market leader both in self-care products and reference priced prescription drugs in Finland. In self-care products Orion grew faster than the market.
- Easyhaler® product family sales increased by 17 per cent.

The work continues.

Patient safety and reliable supply of medications are priorities also during COVID-19 pandemic



MATERIAL THEMES OF SUSTAINABILITY

Ensuring patient safety and reliable supply of medications

Responsibility for employees, the environment and the ethics and transparency of operations



- Ensuring reliable supply of medications is the most important task for Orion at the moment
 - Responding to a surprising spike in demand
 - Prioritising the production of critical products
 - Full utilisation of production capacity
 - Ensuring the availability of raw and starting materials
 - Ensuring the safety of patients in clinical trials is a priority

- Taking care of the health and safety of employees is essential
 - Specific measures taken in critical production and quality control to ensure the continuation of production
 - Reducing non-essential contacts


Orion's sustainability report for 2019 was published in April

Corporate responsibility - targets and performance in 2019 CORPORATE RESPONSIBILITY 2019 FOCUS AREA TARGET PERFORMANCE Patient safety and Ensuring availability of pharmaceutical products ensuring reliable supply Ensuring patient safety of medications Improving energy efficiency Environment Reducing greenhouse gas emissions

Reducing the share of hazardous waste from total waste

$\overline{\sim}$	Responsibility for Orionees	Lost-Time Injury Frequency (LTIF 1) is 3.5 by the end of 2019	
SIN /	for Orionees	Decrease absences due to illness	

	Business ethics and	100% of active packaging material, raw material and product suppliers signed Third Party Code of Conduct	
	transparency	Trainings on anti-corruption and anti-bribery matters.	



Outlook



Outlook for 2020 (provided on 8 July 2020)



Net sales

Orion estimates that in 2020 net sales will be **at a similar level** as in 2019 (net sales in 2019 were EUR 1,051 million).

Operating profit

Operating profit is estimated to be **slightly higher or higher** than in 2019 (in 2019 operating profit was EUR 253 million).



Orion calendar

Interim Report 1-9/2020

21/10/2020

Financial Statement Release for 2020 AGM planned to be held Interim Report 1-3/2021 Half-Year Financial Report Interim Report 1-9/2021

9/2/2021 25/3/2021 27/4/2021 19/7/2021 20/10/2021



